Status:
UNKNOWN
Study of Weekly Radiotherapy for Bladder Cancer
Lead Sponsor:
Institute of Cancer Research, United Kingdom
Collaborating Sponsors:
Cancer Research UK
Conditions:
Bladder Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Background Localised muscle invasive bladder cancer (MIBC) is life-threatening and can cause significant symptoms. Around 50% of patients with MIBC who are referred for radiotherapy are unfit for stan...
Eligibility Criteria
Inclusion
- Written informed consent
- Age ≥18 years
- Histologically confirmed invasive bladder carcinoma (T2-T4a N0 M0; any histological sub-type)
- Unsuitable for radical cystectomy or daily fractionated radiotherapy for any reason (including performance status, co-morbidity, patient refusal)
- Expected survival \>6 months
- WHO performance status 0-3
- Willing to undergo post treatment cystoscopy
Exclusion
- Nodal or metastatic disease
- Concurrent malignancy
- Previous pelvic radiotherapy
- Urinary catheter in-situ
- Any other contra-indication to radiotherapy (e.g. inflammatory bowel disease)
- Unable to attend for post treatment follow up
Key Trial Info
Start Date :
April 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2025
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT01810757
Start Date
April 1 2014
End Date
January 1 2025
Last Update
August 10 2016
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Addenbrooke's Hospital
Cambridge, United Kingdom
2
Velindre Cancer Centre
Cardiff, United Kingdom
3
Ipswich Hospital
Ipswich, United Kingdom
4
St James's University Hospital
Leeds, United Kingdom